Prochon Biotech Ltd.

Omrix Biopharmaceuticals Inc.

Bio Harvest Ltd.

Malkit Azachi

Avner Yayon

Israel Nur

Liliana Bar

Yoheved Hagay

Micha Gladnikoff

Rivka Yatuv

Michal Abargel

Yoav Roth

Hilla Barkay-Olami

Hilla Barkay

The present application describes a large scale process for the in vitro production of an olive cell culture. The application further describes a composition in a form of a powder comprising olive fruit/leaf cells grown in vitro and a method of treating metabolic syndrome disorders, such as, high cholesterol level, comprising administering an effective amount of the composition. The cell line callus culture of olive cells manufactured according to the process of the invention includes high level of hydroxytyrosol, tyrosol, oleuropein and verbascoside.

Olive derived cell culture and methods for preparing and using the same

The invention relates to a large scale process for the in vitro production of a cell culture of pomegranate cells, to a product prepared from such cells and to a composition comprising a complex of pholyphenols, including punicalagin, 1,2,3,4,6-pentagalloyl glucose (PGG) or both.

Pomegranate derived cell culture and methods for preparing and using the same

The disclosure provides a method for treating, reducing, alleviating or preventing metabolic syndrome or metabolic malady, comprising administering a composition comprising a cell line callus culture of fruit cells grown in vitro. Further provided are fruit cells prepared according to a large scale process. The cell line callus culture of grape berry cells manufactured according to the process includes resveratrol in an amount of at least 1000 mg/kg powder.

Process for the large scale production of fruit cells and treatment of diseases with such cells

Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.

Freeze-dried fibrin matrices and methods for preparation thereof

A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.

Removal of plasmin or plasminogen from cryoprecipitate

Methods for producing porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions made by the method of the present invention are useful clinically or as cell-bearing implants.

The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.

Plasma cryoprecipitate substantially free of plasminogen

The present invention relates to porous freeze-dried plasma protein matrices having an open channel structure and a concentration gradient of plasma proteins crosslinked by the action of thrombin, and methods of producing said matrices. The compositions of the present invention are useful clinically, per se or as cell-bearing implants.

Porous plasma protein matrices and methods for preparation thereof

A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6&#x2013;8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.

Growing community of inventors

Rehovot, Israel

Malkit Azachi